Explore 3 Stock Ideas & Industry Insights Download Free Report

888-969-2592
Shopping Cart 0
countryflagCA
Login

Home CompaniesSynairgen plc

Synairgen plc

Healthcare Biotechnology
PortfolioPortfolio WatchlistWatchlist
Company price
None GBX 0.00(0%)
Last update at 2025-05-07T16:00:09.713409Z
Market Cap
14.10M

Momentum Score

…

Synairgen plc discovers and develops drugs for respiratory diseases. It develops SNG001, an inhaled interferon beta for the treatment of COVID-19; inhaled interferon beta (IFN-ß), which is in Phase-II clinical trials for the treatment of asthma caused by the common cold and flu; and IFN-ß that is in Phase-II clinical trials for the treatment or prevention of chronic obstructive pulmonary disease. The company was incorporated in 2004 and is headquartered in Southampton, the United Kingdom.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

52 Week Price Range
6.01
Low
17.50
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High

Key Metrics*

Previous Close
0.95
Dividend Yield
-
Revenue TTM
0.08M
Revenue Per Share
0.00
Gross Profit TTM
0.10M
Debt / Equity
0.00
ROE
-48.86%
Net Debt
-15.93M
ROCE
-100.12%
Diluted EPS TTM
-0.05

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2021-03-30 2020-12-31 2020-03-30
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2021-03-30 2020-12-31 2020-03-30
Income before tax -20.09M -57.86M - -17.73M -
Net income -17.64M -48.66M - -13.92M -
Selling general administrative 5.36M 5.01M - 2.25M -
Reconciled depreciation 0.10M 0.20M - 0.26M -
Ebit -20.30M -57.87M -17.74M -17.74M -4.82M
Ebitda -19.99M -57.66M - -17.46M -
Depreciation and amortization 0.31M 0.21M - 0.28M -
Operating income -20.30M -57.87M - -17.74M -
Other operating expenses 20.30M 57.87M - 17.74M -
Interest expense 0.21M 0.00M 0.00M 0.01M 0.00M
Tax provision -2.45M -9.19M - -3.82M -
Interest income 0.21M 0.01M - 0.02M -
Net interest income 0.21M 0.01M - 0.01M -
Income tax expense -2.45M -9.19M -3.82M -3.82M -0.91M
Total revenue 0.00M 0.00M - 0.00M -
Total operating expenses 20.30M 57.87M - 17.74M -
Total other income expense net 0.21M 0.01M - 0.01M -
Net income from continuing ops -17.64M -48.66M - -13.92M -
Net income applicable to common shares -17.64M -48.66M -13.92M -13.92M -3.88M
Breakdown 2022-12-31 2021-12-31 2021-03-30 2020-12-31 2020-03-30
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2021-03-30 2020-12-31 2020-03-30
Total assets 23.53M 44.64M - 88.55M -
Intangible assets 0.04M 0.05M - 0.04M -
Other current assets 0.00M 10.59M - 13.14M -
Total liab 3.25M 7.64M - 3.41M -
Total stockholder equity 20.27M 37.00M - 85.14M -
Other current liab - 3.48M - 1.74M -
Common stock 2.01M 2.01M 2.00M 2.00M 1.09M
Capital stock 2.01M 2.01M - 2.00M -
Retained earnings -107.47M -90.74M -42.59M -42.59M -27.59M
Cash 15.93M 33.83M - 74.98M -
Total current liabilities 3.25M 7.64M 3.41M 3.41M 1.69M
Net debt -15.93M -33.83M - -74.85M -
Short term debt - - - 0.13M -
Short long term debt total - - - 0.13M -
Other stockholder equity 125.73M 125.73M 0.48M 125.73M 0.48M
Property plant equipment 0.09M 0.17M 0.34M 0.34M 0.56M
Total current assets 23.40M 44.41M 88.16M 88.16M 3.50M
Net tangible assets 20.23M 36.95M 85.10M 85.10M 2.24M
Short term investments 3.75M - - - -
Net receivables 1.31M 9.61M 13.14M 4.32M 1.00M
Inventory - 0.00M 0.04M 0.04M 0.04M
Accounts payable 3.25M 7.64M 3.28M 3.28M 1.49M
Common stock total equity - - - 2.00M -
Non current assets total 0.13M 0.23M - 0.39M -
Capital lease obligations - 0.00M - 0.13M -
Breakdown 2022-12-31 2021-12-31 2021-03-30 2020-12-31 2020-03-30
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2021-03-30 2020-12-31 2020-03-30
Investments -3.62M -0.02M - -0.04M 0.05M
Change to liabilities -4.38M 4.36M 1.79M 1.79M 0.71M
Total cashflows from investing activities -3.62M -0.02M -0.04M -0.04M 0.07M
Net borrowings - -0.12M -0.20M -0.20M -0.20M
Total cash from financing activities 0.00M -0.11M 96.39M 96.39M 96.39M
Net income -20.09M -57.86M -13.92M -17.73M -3.88M
Change in cash -17.90M -41.15M 72.52M 72.52M -2.83M
Begin period cash flow 33.83M 74.98M 74.98M 2.45M 2.45M
End period cash flow 15.93M 33.83M 74.98M 74.98M 2.45M
Total cash from operating activities -14.29M -41.02M -23.82M -23.82M -2.90M
Issuance of capital stock 0.00M 0.01M - 99.78M -
Depreciation 0.10M 0.20M 0.26M 0.26M 0.16M
Other cashflows from investing activities 0.14M 0.01M 0.03M 0.03M 0.03M
Change to inventory 0.00M 0.04M - 0.04M 0.01M
Change to account receivables 0.29M 7.84M -9.24M -9.24M 0.08M
Other cashflows from financing activities -3.62M -0.13M -4.49M -3.40M -4.49M
Change to netincome 7.35M -4.79M -2.71M -2.71M 0.02M
Capital expenditures 0.01M 0.03M 0.04M 0.08M 0.01M
Change in working capital -4.09M 12.24M - -7.46M -
Stock based compensation 0.92M 0.51M - 0.21M -
Other non cash items 8.88M -0.01M - -0.01M -
Free cash flow -14.29M -41.05M - -23.89M -

Peer Comparison*

Sector: Healthcare Industry: Biotechnology

Stock Name
Change
(GBX)
Price
(GBX)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
GNS
Genus PLC		 18.00
0.78%		 2340.00 36.08 26.18 2.53 3.46 2.92 15.38
ONT
Oxford Nanopore Technologies Ltd		 10.60
4.93%		 225.60 - - 4.71 2.50 4.23 -8.89
OXB
Oxford BioMedica PLC		 5.00
0.95%		 532.00 - 208.33 4.05 7.60 4.42 308.96
AVCT
Avacta Group PLC		 -1.00
1.60%		 61.50 - - 2849.46 1929.84 2525.51 -12.04

Profile*

Synairgen plc

Synairgen plc discovers and develops drugs for respiratory diseases. It develops SNG001, an inhaled interferon beta for the treatment of COVID-19; inhaled interferon beta (IFN-ß), which is in Phase-II clinical trials for the treatment of asthma caused by the common cold and flu; and IFN-ß that is in Phase-II clinical trials for the treatment or prevention of chronic obstructive pulmonary disease. The company was incorporated in 2004 and is headquartered in Southampton, the United Kingdom.

Mailpoint 810, Southampton, United Kingdom, SO16 6YD

44 23 8051 2800

https://www.synairgen.com

30

Name Title Year Born
Mr. Richard Marsden CEO, MD & Exec. Director 1968
Prof. Stephen T. Holgate CBE, M.D. Co-Founder, Non-Exec. Director & Member of Scientific Advisory Board 1948
Mr. John Ward CFO & Exec. Director 1962
Dr. Phillip David Monk Chairman of Scientific Advisory Board, Chief Scientific Officer & Exec. Director 1969
Prof. Donna Davies Co-Founder & Member of Scientific Advisory Board NA
Prof. Ratko Djukanovic Co-Founder & Member of Scientific Advisory Board NA
Ms. Brooke S Clarke Sr. VP & Head of Communications NA
Dr. Gareth E. Walters Ph.D. Chief Regulatory Officer 1959
Ms. Jody Brookes Sr. VP & Head of Clinical Operations NA
Mr. Richard Hennings Chief Commercial Officer 1970

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

ITH
CAD 2.15
+27.68%
HG
CAD 4.11
+19.13%
PPTA
CAD 27.74
+17.99%
UCU
CAD 2.10
+17.32%
GAU
CAD 3.49
+16.72%
TSU
CAD 29.67
-29.71%
PXT
CAD 19.73
-16.91%
LAS-A
CAD 230.50
-9.25%
IFP
CAD 13.50
-8.35%
NFI
CAD 24.01
-7.80%

Equity Sectors*

  • Basic Materials

    +3.74%

  • Communication Services

    +0.56%

  • Consumer Cyclical

    -0.34%

  • Consumer Defensive

    +0.11%

  • Energy

    +1.33%

  • Financial Services

    -0.26%

  • Healthcare

    +2.54%

  • Industrials

    -0.11%

  • Real Estate

    -0.23%

  • Technology

    +1.91%

  • Utilities

    +1.05%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Support

Hi! How can we help you today?

Loading…